Ramani P, Hart I R, Balkwill F R
Int J Cancer. 1986 Apr 15;37(4):563-8. doi: 10.1002/ijc.2910370415.
A recombinant human hybrid alpha interferon (rIFN-alpha A/D) with antiviral, immunomodulating and cell-growth-inhibitory activity on murine cells strongly inhibited the development of experimental pulmonary metastases of the Colo 26 adenocarcinoma in BALB/c mice. Twenty-one days after i.v. injection of 5 X 10(4) cells, 8/8 control mice had greater than 200 lung tumour nodules whereas 1/6 mice receiving 500 ng rIFN-alpha A/D had one lung tumour nodule and the other 5 mice were tumour-free. Equally strong inhibition was seen in immunodeficient BALB/c nu/nu (athymic) and beige nu/nu (athymic and NK-deficient) mice. Scheduling experiments in vivo showed that the most important time of IFN treatment was from the day of tumour cell injection to day 5, although statistically significant reductions in lung tumour nodule number and lung weight were seen even when IFN treatment was started 7 days after cell injection. rIFN-alpha A/D was cytostatic to Colo 26 in vitro, causing 50% or more inhibition of cell growth or colony number at IFN levels that could be achieved in the sera of IFN-treated mice. Although rIFN-alpha A/D stimulated NK-cell activity in BALB/c mice, Colo 26 cells were resistant in vitro to such cells whether from control or IFN treated mice.
一种对鼠细胞具有抗病毒、免疫调节和细胞生长抑制活性的重组人杂交α干扰素（rIFN-αA/D），强烈抑制了BALB/c小鼠中Colo 26腺癌实验性肺转移的发展。静脉注射5×10⁴个细胞21天后，8/8只对照小鼠有超过200个肺肿瘤结节，而接受500 ng rIFN-αA/D的小鼠中，1/6有1个肺肿瘤结节，其他5只小鼠无肿瘤。在免疫缺陷的BALB/c裸鼠（无胸腺）和米色裸鼠（无胸腺且NK细胞缺陷）中也观察到了同样强烈的抑制作用。体内实验安排表明，IFN治疗的最重要时间是从肿瘤细胞注射当天到第5天，尽管即使在细胞注射7天后开始IFN治疗，肺肿瘤结节数量和肺重量在统计学上也有显著减少。rIFN-αA/D在体外对Colo 26具有细胞生长抑制作用，在IFN治疗小鼠血清可达到的IFN水平下，导致细胞生长或集落数量抑制50%或更多。尽管rIFN-αA/D刺激了BALB/c小鼠的NK细胞活性，但Colo 26细胞在体外对来自对照或IFN处理小鼠的此类细胞具有抗性。
